日本大乳高潮视频在线观看-日本大骚b视频在线-日本大香伊一区二区三区-日本道二区免费v-日本道精品一区二区三区-日本道色综合久久影院

Your Position: Home > News > Industry News

FDA Approves Amgen's XGEVA?(denosumab)

2013/6/11??????view:

FDA Approves Amgen's XGEVA? (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

This Approval Provides a New Treatment Option for a Patient Population With High Unmet Medical Need

THOUSAND OAKS, Calif., Dec. 8, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA? (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy. XGEVA was approved and granted Orphan Drug Designation by the FDA, which is reserved for drugs that are intended for the treatment of rare diseases affecting fewer than 200,000 people in the U.S.

HCM is a serious complication in patients with advanced cancer, including those with hematologic malignancies, and indicates poor prognosis.1,2 The condition results from cancer-driven increases in bone resorption, and if untreated, can lead to renal failure, progressive mental impairment, coma and death.1-3

"Our continued study of XGEVA reinforces Amgen's ongoing commitment to address the unmet needs of cancer patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This latest FDA approval for XGEVA provides an important new therapeutic option for patients with a rare condition that cannot be resolved with bisphosphonate therapy."

The approval of XGEVA is based on positive results from an open-label, single-arm study, which enrolled patients with advanced cancer and persistent hypercalcemia after recent bisphosphonate treatment. The primary endpoint was the proportion of patients with a response, defined as albumin-corrected serum calcium (CSC) 11.5 mg/dL (2.9 mmol/L; Common Terminology for Adverse Events [CTCAE] grade 1) within 10 days after the first dose of XGEVA. Secondary endpoints included the proportion of patients who experienced a complete response (defined as CSC 10.8 mg/dL [2.7 mmol/L]) by day 10, time to response and response duration (defined as the number of days from the first occurrence of CSC 11.5 mg/dL). The study achieved its primary endpoint with a response rate at day 10 of 63.6 percent in the 33 patients evaluated. The overall complete response rate was 63.6 percent. The estimated median time to response (CSC 11.5 mg/dL) was nine days, and the median duration of response was 104 days.4,5

The most common adverse reactions in patients receiving XGEVA for hypercalcemia of malignancy were nausea, dyspnea, decreased appetite, headache, peripheral edema, vomiting, anemia, constipation and diarrhea.5

For patients with HCM, XGEVA is administered as a subcutaneous injection (120 mg) every four weeks with additional doses of 120 mg on days eight and 15 of the first month of therapy.5

XGEVA binds to RANK Ligand (RANKL), a protein essential for the formation, function and survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from bone. XGEVA prevents RANKL from activating its receptor, RANK, on the surface of osteoclasts, thereby decreasing bone destruction and calcium release.5

About Hypercalcemia of Malignancy

Hypercalcemia of malignancy (HCM) is a serious complication in patients with advanced cancer, including those with hematological malignancies.1 In 2012, the estimated prevalence of HCM in cancer patients in the U.S. was 2.7 percent.6 HCM is indicative of poor prognosis and occurs most often in patients with squamous cell cancer (e.g., lung cancer, head and neck cancer), breast cancer, kidney cancer, myeloma and lymphoma.1,2,7 HCM results from cancer-driven increases in bone resorption, and, if untreated, can lead to renal failure, progressive mental impairment, coma and death.1-3

About XGEVA

XGEVA was approved by the FDA for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors in 2010. XGEVA is not indicated for the prevention of SREs in patients with multiple myeloma. In clinical trials, XGEVA demonstrated a clinically meaningful improvement compared to the previous standard of care in preventing SREs. In 2013, XGEVA was approved by the FDA as the first-and-only treatment for adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. (Bioon.com)

 

主站蜘蛛池模板: 久青草视频免费视频播放线路1 | 澳门一级特黄录像免费播黄 | 四虎影视地址 | 亚洲天堂久久 | 亚洲 欧美 另类中文字幕 | 男女生性毛片免费观看 | 变态 调教 视频 国产九色 | 国产一区二区三区乱码网站 | 日本特级爽毛片叫声 | 国产蜜汁tv福利在线 | 日韩一区二区三区不卡 | 天天夜夜骑| 国产一区二区三区免费在线视频 | 在线观看黄p免费 | 久久久久久久综合色一本 | 亚洲精品久久99久久 | 国产小视频91 | 视频日韩 | 欧美成人手机在线视频 | 欧美国产日韩911在线观看 | 日韩不卡一级毛片免费 | 丁香婷婷影音先锋5566 | 亚洲国产高清视频在线观看 | 777色狠狠一区二区三区香蕉 | 久久亚洲国产成人精品性色 | 99热这里只有精品一区二 | 亚洲国产一区二区三区在线观看 | 亚洲成在人天堂一区二区 | 性欧美极品xxxx欧美一区二区 | 香蕉免费一区二区三区在线观看 | 久久婷婷五色综合夜啪 | 久久精品国产2020观看福利色 | 亚洲精品不卡午夜精品 | 亚洲欧美一 | aaa级大片 | 日本黄色不卡视频 | 久久久久久久国产 | 欧美一级一极性活片免费观看 | 久久午夜网 | 国产夜色| 手机看片福利盒子久久 |